Valeant Pharmaceuticals International News

Lower sales and higher taxes pushed Valeant Pharmaceuticals International to a loss for the second quarter, the company said Monday.

Aug. 11, 2008 - Valeant Pharmaceuticals International today announced second quarter financial results for 2008.

The joint ventures will be majority owned by Meda and Valeant will own a minority interest.

As part of an ongoing effort to streamline and focus its operations, Valeant Pharmaceuticals International sold its Western and Eastern European businesses to specialty pharma company Meda AB for $392 million ...

Under the terms of the agreement, Meda will pay $392 million in cash for the Valeant subsidiaries in those markets, and the rights to all products and licenses currently marketed by Valeant in the divested ...

The recovery rating change stems from the company's notice of full redemption of the $300 million in 7% senior notes which is deemed senior to the convertible subordinated notes, said Standard & Poor's credit ...

The executive vice president and chief administrative officer of Valeant Pharmaceuticals International, a specialty pharmaceutical company, bought 2,049 shares of common stock, according to a Securities and ...

MBIA Inc. issued the following statement in response to questions concerning the impact of Moody's Investors Service's downgrade of MBIA Insurance - PHILADELPHIA-- --Sunoco, Inc.

ALISO VIEJO, Calif. - Valeant Pharmaceuticals International today announced that it will redeem all of the $300 million aggregate principal amount outstanding of its 7% Senior Notes due 2011 .

Valeant Pharmaceuticals International said Thursday that its mid-stage hepatitis C candidate taribavirin could replace a drug used in a common treatment regimen.

Companies Featured in This Article: Wells Fargo, Jarden, Valeant Pharmaceuticals International, Allied Capital, Marathon Acquisition, Mobile Mini, Unitrin, Ram Holdings, BGC Partners, UCBH Holdings, Capital ...

Jun 10, 2008 - Valeant Pharmaceuticals International announced today that it has divested its Argentina commercial operations to one of the leading pharmaceutical companies in Argentina.

GuruFocus News Filed Under: HUN , GE , DKS , IMA , VRX , Filed Under: HUN , GE , DKS , IMA , VRX , Filed Under: HUN , GE , DKS , IMA , VRX , Filed Under: HUN , GE , DKS , IMA , VRX , Filed Under: HUN , GE , DKS ...

ALISO VIEJO, Calif.-- --Valeant Pharmaceuticals International today announced members of its senior management team will make a presentation at the Goldman Sachs - 06/04/2008 - 04:30 PM LOS ANGELES-- --TOMY ...

Valeant Pharmaceuticals International today announced members of its senior management team will make a presentation at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference on Thursday, June 12, ...

Health-care product company Covidien appointed Charles "Chuck" Bramlage as president of pharmaceutical products, effective immediately, Covidien announced Thursday.

Celgene Corporation today announced its presentation at The Seventh Annual JMP Securities Research Conference on Wednesday, May 21, 2008 - 05/19/2008 - 04:30 PM ALISO VIEJO, Calif.-- --Valeant Pharmaceuticals ...

Valeant Pharmaceuticals today announced that the Food and Drug Administration has entered an administrative order "in the public interest" to stay the approval of generic fluorouracil cream 5% until May 30, ... via Freshnews

Laurie Little - VP IR Mike Pearson, Chairman and CEO Peter Blott - EVP, CFO Analysts Michael Tong - Wachovia Capital John Boris - Bear Stearns Hank Rauch - Liberty Mutual Greg Gilbert - Merrill Lynch Rajeev ... via Seeking Alpha

“We filed suit because we disagree with the FDA's decision and we are concerned for the safety of our patients suffering from basal cell carcinoma”

Valeant Pharmaceuticals today announced that Spear Pharmaceuticals has agreed not to market, sell or ship a generic fluorouracil cream 5% pursuant to a stay in Valeant's legal case against the Food and Drug ... via Freshnews